When.com Web Search

  1. Ads

    related to: antibody drug conjugate manufacturing process

Search results

  1. Results From The WOW.Com Content Network
  2. Antibody–drug conjugate - Wikipedia

    en.wikipedia.org/wiki/Antibodydrug_conjugate

    Schematic structure of an antibody–drug conjugate (ADC) Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. [1] Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were ...

  3. Bioconjugation - Wikipedia

    en.wikipedia.org/wiki/Bioconjugation

    Monoclonal antibody ibritumomab conjugated with tiuxetan. Bioconjugation is a chemical strategy to form a stable covalent link between two molecules, at least one of which is a biomolecule. Methods to conjugate biomolecules are applied in various field, including medicine, diagnostics, biocatalysis and materials.

  4. Enfortumab vedotin - Wikipedia

    en.wikipedia.org/wiki/Enfortumab_vedotin

    Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate [6] used for the treatment of urothelial cancer. [4] [7] It is a nectin-4-directed antibody and microtubule inhibitor conjugate. [4] [7] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. [5]

  5. Seagen - Wikipedia

    en.wikipedia.org/wiki/Seagen

    The company, headquartered in Bothell, Washington (a suburb of Seattle), is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus ...

  6. Trastuzumab deruxtecan - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab_deruxtecan

    Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11] [12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal ...

  7. Monoclonal antibody therapy - Wikipedia

    en.wikipedia.org/wiki/Monoclonal_antibody_therapy

    The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. However, the immune response to certain antigens may be inadequate, especially in the elderly.